Choosing the unit of measurement counts: The use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses

Palliative Medicine

Volumn 25, Issue 7, 2011, Pages 725-732

  Svendsen, K ^a,b   Borchgrevink, P C ^a,b   Fredheim, O ^a,b,c   Hamunen, K ^d   Mellbye, A ^b   Dale, O ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TELEMARK HOSPITAL   (Norway)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Analgesics; drug utilization; opioid; pharmacoepidemiology

Indexed keywords

BUPRENORPHINE; CODEINE; DEXTROPROPOXYPHENE; DIHYDROCODEINE; FENTANYL; HYDROMORPHONE; KETOBEMIDONE; MORPHINE; OPIATE; OXYCODONE; PARACETAMOL; PETHIDINE; TRAMADOL;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DENMARK; DRUG USE; HUMAN; NORWAY; SWEDEN;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; COOPERATIVE BEHAVIOR; DATABASES, FACTUAL; DRUG UTILIZATION; FENTANYL; HUMANS; METHADONE; MORPHINE; NORWAY; PAIN; PAIN MEASUREMENT; THERAPEUTIC EQUIVALENCY; WORLD HEALTH ORGANIZATION;

EID: 80054010573     PISSN: 02692163     EISSN: 1477030X     Source Type: Journal    
DOI: 10.1177/0269216311398300     Document Type: Article

References (27)

1. Fredheim OM, Skurtveit S, Breivik H, et al. Increasing use of opioids from 2004 to 2007-Pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain. 2009 ; 14: 289-294
2. Hamunen K, Paakkari P, Kalso E. Trends in opioid consumption in the Nordic countries 2002-2006. Eur J Pain. 2009 ; 13: 954-962
3. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009 ; 18: 1166-1175
4. International Narcotics Control Board. Annual Report: Narcotic Drugs. 2009. http://www.incb.org/pdf/technical-reports/narcotic-drugs/2009/Narcotic- drugs-publication-2009.pdf (accessed October 2010).
5. Hamunen K, Laitinen-Parkkonen P, Paakkari P, et al. What do different databases tell about the use of opioids in seven European countries in 2002?. Eur J Pain. 2008 ; 12: 705-715
6. Guidelines for ATC classification and DDD assignment 2010. 2010, 13th ed.WHO, 2010. WHO ; 2010 :
7. De Conno F, Ripamonti C, Brunelli C. Opioid purchases and expenditure in nine western European countries: 'Are we killing off morphine?. Palliat Med. 2005 ; 19: 179-184 (Pubitemid 40668075)
8. Garcia del Pozo J, Carvajal A, Viloria J, et al. Trends in the consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces morphine. Eur J Clin Pharmacol. 2008 ; 64: 411-415
9. Hudec R, Tisoňová J, Božeková L, et al. Trends in consumption of opioid analgesics in Slovak Republic during 1998-2002. Eur J Clin Pharmacol. 2004 ; 60: 445-448 (Pubitemid 39214900)
10. Dale O, Klepstad P, Kaasa S. The European Union-not united in opioid use. Palliat Med. 2005 ; 19: 177-178 (Pubitemid 40668074)
11. Jarlbaek L, Andersen M, Hallas J, et al. Use of opioids in a Danish population-based cohort of cancer patients. J Pain Symptom Manage. 2005 ; 29: 336-343 (Pubitemid 40602513)
12. Curry E, Palla S, Hung F, et al. Prescribing patterns and purchasing costs of long-acting opioids over nine years at an academic oncology hospital. Am J Health Syst Pharm. 2007 ; 64: 1619-1625 (Pubitemid 47173541)
13. Clausen TG, Eriksen J, Borgbjerg FM. Legal opioid consumption in Denmark 1981-1993. Eur J Clin Pharmacol. 1995 ; 48: 321-325
14. Fredheim OMS, Moksnes K, Borchgrevink PC, et al. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand. 2008 ; 52: 879-889 (Pubitemid 351951756)
15. Norwegian Medicines Agency. Summary of product characteristics, Ketorax. http://www.legemiddelverket.no/custom/Preparatsok/prepSearch-80333.aspx (accessed 13 October 2009).
16. Norwegian Medicines Agency. Summary of product characteristics, Actiq. http://www.legemiddelverket.no/custom/Preparatsok/prepSearch-80333.aspx (accessed 13 October 2009).
17. Klepstad P, Borchgrevink PC, Kaasa S. Effects on cancer patients' health-related quality of life after the start of morphine therapy. J Pain Symptom Manage. 2000 ; 20: 19-26 (Pubitemid 30628578)
18. Cancer pain relief. Geneva: WHO ; 1986 :
19. BackIN. Palliative Medicine Handbook, http://book.pallcare.info/index. php?tid=125 (accessed January 2009).
20. Souter K, Fitzgibbon D. Equianalgesic dose guidelines for long-term opioid use: Theoretical and practical considerations. Semin Anesth. 2004 ; 23: 271-280 (Pubitemid 40164932)
21. MacAuleyD. Narcotic analgesic converter. http://www.globalrph.com/ narcotic.cgi. (accessed January 2009).
22. Wall PD, Melzack R, McMahon SB, et al Wall and Melzack's Textbook of Pain. Philadelphia: Elsevier Churchill Livingstone ; 2006 :
23. Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: Results of a retrospective cohort study. Clin Ther. 2005 ; 27: 225-237 (Pubitemid 40462016)
24. Patanwala AE, Duby J, Waters D, et al. Opioid conversions in acute care. Ann Pharmacother. 2007 ; 41: 255-266
25. Divvela S, Williams A, Meives C, et al. Opioid analgesics: Comparison of pharmacokinetics and equianalgesic doses. Hosp Pharm. 2006 ; 42: 1130-1135 (Pubitemid 44876905)
26. Anderson R, Saiers JH, Abram S, et al. Accuracy in equianalgesic dosing. conversion dilemmas. J Pain Symptom Manage. 2001 ; 21: 397-406 (Pubitemid 32452140)
27. Ohqvist G, Hallin R, Gelinder S, et al. A comparison between morphine, meperidine and ketobemidone in continuous intravenous infusion for postoperative relief. Acta Anaesthesiol Scand. 1991 ; 35: 44-48